SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date changed from estimate of Oct 1, 2026 to Oct 6, 2026 Show 4 more changesShow less
    • Interventions: Atezolizumab (Biological), Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), CXCR1/2 Inhibitor SX-682 (Drug), Computed… to Atezolizumab (Biological), Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), CXCR1/2 Inhibitor SX-682 (Drug), Computed…
    • Eligibility criteria expanded, about 57 words
    • Secondary endpoints: details revised at 1 of 7 entries
    • Site details revised
  2. Re-verified, no change to tracked fieldsv6
  3. Recruitment opened
    • Start date: Sep 1, 2026 to Oct 1, 2026
    • Site details revised
    v5
  4. Re-verified, no change to tracked fieldsv4
  5. Start date: Jun 1, 2026 to Sep 1, 2026v3
  6. Start date: Mar 1, 2026 to Jun 1, 2026v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests how well SX-682 and atezolizumab works for the treatment of non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic), and has come back after a period of improvement (recurrent). SX-682 blocks proteins that may be able to stimulate the immune system to kill and eliminate tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving SX-682 and atezolizumab may be effective for the treatment of advanced or metastatic, recurrent NSCLC.
Trial Details
NCT Number NCT07322341
Lead Sponsor University of Washington
Collaborators: Genentech, Inc., Syntrix Biosystems, Inc., National Cancer Institute (NCI)
Conditions
(from sponsor)		 Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Related terms Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov